IRVINE, CA, and HERSTAL, BELGIUM – January 28, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participating at the following key conferences during the first half of 2016:
Bank Degroof Petercam Healthcare CEO Seminar on 03 February, Hotel Bloom Brussels, Belgium
LSP Biocapital Europe on 09 March, Sofitel Legend Amsterdam, The Grand, The Netherlands
European Association of Urology Annual Congress, 11-15 March, Messe Munich International, Germany
KBC Securities Benelux Biotech & Healthcare Conference on 22 March, KBC Securities Brussels, Belgium
American Urology Association Meeting, 06-10 May, Convention Center of San Diego, California
FlandersBio Knowledge for Growth on 26 May, ICC Ghent, Belgium
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.